YM BioSciences Inc. YMI, today reported preclinical results for its JAK1/JAK2 inhibitor CYT387 in multiple myeloma, published in the advance online edition of Leukemia on July 26, 2011. The results demonstrate that CYT387 can inhibit MM cellular proliferation in a time- and dose-dependent manner and induce apoptosis (cell death) in human myeloma cell lines.
Moreover, when used in combination with the conventional anti-MM therapies melphalan and bortezomib, CYT387 synergized in killing HMCL and primary MM tumor cells.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in